Literature DB >> 2539391

Alpha 1-antitrypsin deficiency caused by the alpha 1-antitrypsin Nullmattawa gene. An insertion mutation rendering the alpha 1-antitrypsin gene incapable of producing alpha 1-antitrypsin.

D Curiel1, M Brantly, E Curiel, L Stier, R G Crystal.   

Abstract

alpha 1-Antitrypsin (alpha 1AT) deficiency is a hereditary disorder associated with reduced serum alpha 1AT levels and the development of pulmonary emphysema. An alpha 1AT gene is defined as "Null" when no alpha 1AT in serum is attributed to that alpha 1AT gene. Although all alpha 1AT Null genes have identical phenotypic consequences (i.e. no detectable alpha 1AT in the serum), different genotypic mechanisms can cause the Null state. This study defines the molecular basis for the alpha 1AT gene Nullmattawa, identified and cloned from genomic DNA of an individual with the Null-Null phenotype and emphysema resulting from the heterozygous inheritance of the Nullmattawa and Nullbellingham genes. Sequencing of exons Ic-V and all exon-intron junctions of the Nullmattawa gene demonstrated it was identical to the common normal M1(Val213) alpha 1AT gene except for the insertion of a single nucleotide within the coding region of exon V, causing a 3' frameshift with generation of a premature stop signal. Family analysis using oligonucleotide probes specific for the Nullmattawa sequence demonstrated the gene was inherited in an autosomal fashion. Examination of blood monocytes demonstrated that a normal-sized, 1.8-kb alpha 1AT mRNA transcript is associated with the Nullmattawa gene and in vitro translation of mRNA with the Nullmattawa mutation showed it translated at a normal rate but produced a truncated alpha 1AT protein. Additionally, retroviral transfer of the alpha 1AT Nullmattawa cDNA to murine fibroblasts demonstrated no detectable intracellular or secreted alpha 1AT, despite the presence of alpha 1AT Nullmattawa mRNA transcripts. These findings are consistent with the concept that the molecular pathophysiology of Nullmattawa is likely manifested at a posttranslational level. The identification of the Nullmattawa gene supports the concept that Null alpha 1AT alleles represent a heterogenous group in which very different mechanisms cause the identical phenotypic state.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539391      PMCID: PMC303800          DOI: 10.1172/JCI113994

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

1.  Molecular basis of a mutational hot spot in the lysozyme gene of bacteriophage T4.

Authors:  Y Okada; G Streisinger; J E Owen; J Newton; A Tsugita; M Inouye
Journal:  Nature       Date:  1972-04-14       Impact factor: 49.962

2.  1 -Antitrypsin deficiency: a variant with no detectable 1 -antitrypsin.

Authors:  R C Talamo; C E Langley; C E Reed; S Makino
Journal:  Science       Date:  1973-07-06       Impact factor: 47.728

3.  Frame shift mutations near the beginning of the lysozyme gene of bacteriophage T4.

Authors:  Y Okada; G Streisinger; J Emrich; J Newton; A Tsugita; M Inouye
Journal:  Science       Date:  1968-11-15       Impact factor: 47.728

4.  Frameshift mutations and the genetic code. This paper is dedicated to Professor Theodosius Dobzhansky on the occasion of his 66th birthday.

Authors:  G Streisinger; Y Okada; J Emrich; J Newton; A Tsugita; E Terzaghi; M Inouye
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1966

5.  Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.

Authors:  R Mann; R C Mulligan; D Baltimore
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

6.  Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs.

Authors:  P A Krieg; D A Melton
Journal:  Nucleic Acids Res       Date:  1984-09-25       Impact factor: 16.971

7.  beta-Thalassemia in Chinese: use of in vivo RNA analysis and oligonucleotide hybridization in systematic characterization of molecular defects.

Authors:  T C Cheng; S H Orkin; S E Antonarakis; M J Potter; J P Sexton; A F Markham; P J Giardina; A Li; H H Kazazian
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

8.  Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function.

Authors:  H Loebermann; R Tokuoka; J Deisenhofer; R Huber
Journal:  J Mol Biol       Date:  1984-08-15       Impact factor: 5.469

9.  Unstable beta-globin mRNA in mRNA-deficient beta o thalassemia.

Authors:  L E Maquat; A J Kinniburgh; E A Rachmilewitz; J Ross
Journal:  Cell       Date:  1981-12       Impact factor: 41.582

10.  Molecular characterization of seven beta-thalassemia mutations in Asian Indians.

Authors:  H H Kazazian; S H Orkin; S E Antonarakis; J P Sexton; C D Boehm; S C Goff; P G Waber
Journal:  EMBO J       Date:  1984-03       Impact factor: 11.598

View more
  20 in total

1.  Molecular characterisation of two alpha-1-antitrypsin deficiency variants: proteinase inhibitor (Pi) Null(Newport) (Gly115----Ser) and (Pi) Z Wrexham (Ser-19----Leu).

Authors:  A Graham; N A Kalsheker; F J Bamforth; C R Newton; A F Markham
Journal:  Hum Genet       Date:  1990-10       Impact factor: 4.132

2.  Coordinated DNA methylation and gene expression changes in smoker alveolar macrophages: specific effects on VEGF receptor 1 expression.

Authors:  Robert A Philibert; Rory A Sears; Linda S Powers; Emma Nash; Thomas Bair; Alicia K Gerke; Ihab Hassan; Christie P Thomas; Thomas J Gross; Martha M Monick
Journal:  J Leukoc Biol       Date:  2012-03-16       Impact factor: 4.962

Review 3.  Molecular biology and respiratory disease. 7. The alpha 1 antitrypsin gene and chronic lung disease.

Authors:  N Kalsheker; K Morgan
Journal:  Thorax       Date:  1990-10       Impact factor: 9.139

4.  Molecular characterisation of three alpha-1-antitrypsin deficiency variants: proteinase inhibitor (Pi) nullcardiff (Asp256----Val); PiMmalton (Phe51----deletion) and PiI (Arg39----Cys).

Authors:  A Graham; N A Kalsheker; C R Newton; F J Bamforth; S J Powell; A F Markham
Journal:  Hum Genet       Date:  1989-12       Impact factor: 4.132

5.  Can we change a genetically determined future?

Authors:  Lígia Rodrigues Fernandes; Luis Vaz Rodrigues; Filipa Costa; Yvette Martins
Journal:  BMJ Case Rep       Date:  2015-05-15

6.  DNA polymorphisms associated with a new alpha 1-antitrypsin PIQ0 variant (PIQ0riedenburg).

Authors:  W Poller; J P Faber; S Weidinger; K Olek
Journal:  Hum Genet       Date:  1991-03       Impact factor: 4.132

7.  Highly variable clinical course in severe alpha 1-antitrypsin deficiency--use of polymerase chain reaction for the detection of rare deficiency alleles.

Authors:  W Poller; J P Faber; K Olek
Journal:  Klin Wochenschr       Date:  1990-09-03

8.  A null deficiency allele of alpha 1-antitrypsin, QOludwigshafen, with altered tertiary structure.

Authors:  G C Frazier; M A Siewertsen; M H Hofker; M G Brubacher; D W Cox
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

9.  Only three mutations account for almost all defective alleles causing adenine phosphoribosyltransferase deficiency in Japanese patients.

Authors:  N Kamatani; M Hakoda; S Otsuka; H Yoshikawa; S Kashiwazaki
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

10.  Identification and DNA sequence analysis of 15 new alpha 1-antitrypsin variants, including two PI*Q0 alleles and one deficient PI*M allele.

Authors:  J P Faber; W Poller; S Weidinger; M Kirchgesser; R Schwaab; F Bidlingmaier; K Olek
Journal:  Am J Hum Genet       Date:  1994-12       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.